WHO updates list of essential medicines to include key cancer, diabetes treatments

The World Health Organization (WHO) has updated its Essential Medicines Lists, adding significant treatments including PD-1/PD-L1 immune checkpoint inhibitors for various cancers and GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) for diabetes and obesity. These revisions, which influence public procurement and reimbursement in over 150 countries, expand market access for these drug classes, yet the WHO simultaneously stressed the critical need for affordability and generic competition, particularly for high-priced GLP-1s, signaling potential future pricing pressures despite increased volume.

Analysis

The World Health Organization (WHO) has updated its Model Lists of Essential Medicines (EML), a significant regulatory and policy development that influences procurement and reimbursement in over 150 countries. The inclusion of new, high-value drug classes represents a major long-term catalyst for market access, particularly in low- and middle-income countries. Specifically, the addition of PD-1/PD-L1 immune checkpoint inhibitors, such as pembrolizumab, for several metastatic cancers validates their high clinical benefit, as the WHO's rigorous criteria only admit therapies proven to extend life by at least 4-6 months. Similarly, the endorsement of GLP-1 receptor agonists, including semaglutide and tirzepatide, for type 2 diabetes with specific comorbidities, provides a clear pathway for public sector adoption. However, this expansion of access is coupled with a significant caveat. The WHO explicitly highlighted the high prices of these medicines as a barrier and endorsed strategies to improve affordability, including encouraging generic competition and implementing dose optimization. This signals that while inclusion on the EML will likely drive significant volume growth for these drug classes, it will also intensify pricing scrutiny and pressure from governments and public health bodies, creating a potential headwind for long-term margins.

Key Decisions for Investors

• Investors should view this development as a long-term positive for volume growth in oncology and diabetes markets, particularly for companies with leading PD-1/PD-L1 and GLP-1 assets, but must simultaneously factor in increased risk of government-led pricing pressure and advocacy for generic entry.
• Monitor for policy changes in key emerging markets that adopt the new EML, as the speed and nature of their reimbursement and pricing negotiations for these newly listed drugs will be a critical indicator of future revenue streams.
• It is prudent to assess the specific patient populations targeted by the WHO's recommendations, such as type 2 diabetics with established cardiovascular or kidney disease, as this defines the immediate addressable public market, which may be narrower than the broader commercial market.
• Consider this a validation of the clinical superiority of the included drug classes, which may strengthen their competitive moat against less effective alternatives, even as pricing becomes a more central point of negotiation.